Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that spironolactone may improve acne and some ovarian functions in patients with irregular menstrual periods and androgenic symptoms, while causing few side effects.

This study discusses the use of oral contraceptives as a treatment for hyperandrogenism, showing improvement in hirsutism and acne for many women and possibly providing metabolic benefits with certain formulations.

This study reported that classic anovulatory PCOS was the most common androgen excess disorder, followed by mild ovulatory PCOS and idiopathic hyperandrogenism, among patients evaluated for clinical hyperandrogenism.

This review examines the use of natural remedies, including various herbs, for treating polycystic ovary syndrome, but reports no new clinical results.

This study defined menstrual phase-specific reference intervals for circulating androgen levels in young women, highlighting that anovulatory females showed higher androgen, LH, and FSH levels compared to ovulatory females.

This study found that PCOS is common among Iranian women, with phenotypes involving hyperandrogenism exhibiting worse lipid profiles and higher rates of metabolic syndrome compared to healthy women.

This consensus report reviews current knowledge and identifies knowledge gaps concerning the various health aspects of polycystic ovary syndrome, without presenting new clinical findings.

This review discusses treatments for polycystic ovary syndrome, including lifestyle changes, oral contraceptives, and various medications, and reports no new clinical findings; the authors highlight the potential of statins and inositol for managing symptoms.

This review discusses insulin resistance in women with polycystic ovary syndrome and reports no new clinical results; it highlights the potential benefits of lifestyle changes and insulin-sensitizing drugs.

This article reviews the diagnostic criteria and management strategies for polycystic ovary syndrome but reports no new clinical findings; it highlights associated health risks and recommended treatments.

In this study, adding α-lactalbumin to myo-inositol treatment improved ovulation rates, menstrual cycle duration, and hyperandrogenism in women with PCOS more effectively than myo-inositol alone, suggesting potential benefits for those resistant to inositol treatment.

This article discusses the complexities of diagnosing and managing polycystic ovary syndrome, highlighting the challenges related to fertility treatment criteria, insulin resistance, and long-term health implications, but reports no new clinical findings.

This study found that anovulatory PCOS was the most common phenotypic variant among women with menstrual irregularities seeking treatment, and no cases of obese PCOS were observed.

This review discusses various aspects of polycystic ovary syndrome, including its prevalence, diagnosis, and treatment options, and reports no new empirical results.

This review discusses updated recommendations and recent studies on PCOS management but reports no new clinical results, questioning whether the 2018 global guideline will change practice.

This study suggests that weight loss can improve fertility outcomes in overweight and obese women with PCOS, and letrozole should be considered the new first-line treatment over clomiphene citrate for anovulatory infertility in this population.

This abstract reviews the characteristics and health risks associated with polycystic ovary syndrome and does not report new findings, highlighting the syndrome's multifactorial nature.

This study reported an association between the rs6259 polymorphism affecting SHBG levels and PCOS in most Indian women, suggesting a potential genetic link in this population.

This article reviews the potential mechanisms underlying polycystic ovary syndrome, emphasizing insulin resistance and hormone dysregulation, and reports no new research findings.

This review discusses diagnostic criteria, phenotypes, and therapies for polycystic ovarian syndrome, emphasizing an individualized treatment approach based on the multifactorial nature of the disease; it reports no clinical results.

This review discusses the management of polycystic ovary syndrome and highlights the benefits of an integrative approach combining lifestyle, pharmacological, and herbal treatments, but reports no new research findings.

This review details the 2023 International Guideline update for assessing and managing polycystic ovary syndrome, which provides evidence-based recommendations to improve care and patient outcomes but notes the remaining low to moderate quality of evidence.

This review discusses the pathophysiological characteristics and treatment options for polycystic ovary syndrome, reporting no new clinical results; the authors emphasize combining non-pharmacological measures with pharmacological treatments for optimal patient management.

This review discusses the pathophysiology of polycystic ovary syndrome and its non-pharmacological and pharmacological treatment options, but reports no new clinical results.

This paper summarizes proceedings from a PCOS Special Interest Group, reporting recent advances in the understanding of PCOS follicular abnormalities, associated cardiovascular risks, and dermatological issues, but does not present new clinical findings.

Finasteride helps induce ovulation in nonresponder PCOS women.

This article reviews the challenges in diagnosing mild hyperandrogenism in adolescent girls, discussing potential causes like PCOS and treatment options, but reports no new clinical results.

This article reviews the differential diagnosis of mild hyperandrogenism in adolescent girls, discussing potential causes such as PCOS and nonclassic adrenal hyperplasia, but presents no new data.

This study found that in women with PCOS, insulin resistance is closely associated with hyperandrogenism, indicating it may independently predict increased androgen levels.

In this review, the authors aim to improve the differential diagnosis between hyperandrogenic PCOS and NCAH, which could lead to more personalized treatment strategies for patients experiencing hyperandrogenism.